If I were to weigh this as an investor, here’s how I see the proposition:
Short term / Listing gains could be strong: Given the high GMP, strong subscription (especially from institutions), and positive sentiment, there’s a good chance for listing profits.
Long-term potential is reasonable but not without caveats: The business has good fundamentals, but actual earnings growth, managing royalty & tax liabilities, maintaining margins, and competing in a fast changing sector will be key.
Risk tolerance matters: For someone comfortable with risks (governance, regulatory, competition), this IPO can be attractive. For very risk-averse investors, the OFS nature, high valuations, and uncertain liability issues mean caution is warranted.
If I were to weigh this as an investor, here’s how I see the proposition:
Short term / Listing gains could be strong: Given the high GMP, strong subscription (especially from institutions), and positive sentiment, there’s a good chance for listing profits.
Long-term potential is reasonable but not without caveats: The business has good fundamentals, but actual earnings growth, managing royalty & tax liabilities, maintaining margins, and competing in a fast changing sector will be key.
Risk tolerance matters: For someone comfortable with risks (governance, regulatory, competition), this IPO can be attractive. For very risk-averse investors, the OFS nature, high valuations, and uncertain liability issues mean caution is warranted.
Stay Connected, Stay Informed –
Don’t miss out on exclusive updates, market trends, and real-time investment opportunities. Be the first to know about the latest unlisted stocks, IPO announcements, and curated Fact Sheets, delivered straight to your WhatsApp.